MedTrace Logo

VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease

NCT04587323 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-02-27

No results posted yet for this study

Summary

To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.

Conditions

  • COVID-19 Disease

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Dylan Addis, MD · University of Alabama at Birmingham

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-22
Primary Completion
2025-10-06
Completion
2025-10-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04587323 on ClinicalTrials.gov